Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025

Strasbourg (France), June 3, 2025, 8:00 a.m. CET – Transgene(Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced it will host alive webcastto discuss the latestpositive clinical data from its individualized neoantigen cancer vaccine, TG4050, presented at the 2025 American Society of Clinical Oncology ( ASCO ) Annual Meeting (see press release here).The webcast will take place onJune 6, 2025...

Illkirch Graffenstaden, 03/06/2025 (informazione.news - comunicati stampa - economia)

(Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced it will host a to discuss the latest , presented at the 2025 American Society of Clinical Oncology ( ) Annual Meeting (see press release ).

The webcast will take place on at 9:00 a.m. ET / 3:00 p.m. CET, and will feature Transgene's management together with , MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology). They will , .

A replay of the call will be available on the Transgene website (www.transgene.com) following the live event.

***

myvac®
myvac® myvac

Attachment